Optic
Optic provides an AI-native platform that automates evaluation, discovery, and prioritization of drug candidates to accelerate pharmaceutical R&D. It combines generative and agentic AI with ligand-based and structure-based molecular models plus LLM-driven workflows to predict potency, safety, and manufacturability and to automate in-licensing, diligence, and commercialization tasks. The platform includes molecular similarity search, clinical trial and patent search integrations, and runs on GPU-accelerated infrastructure (e.g., NVIDIA T4) delivered as a SaaS subscription. Typical customers are biopharma and biotech teams collaborating with Optic to scale preclinical pipelines and business due diligence. Optic aims to create a closed-loop, intelligent drug development engine that integrates scientific and business AI.
Optic
Optic provides an AI-native platform that automates evaluation, discovery, and prioritization of drug candidates to accelerate pharmaceutical R&D. It combines generative and agentic AI with ligand-based and structure-based molecular models plus LLM-driven workflows to predict potency, safety, and manufacturability and to automate in-licensing, diligence, and commercialization tasks. The platform includes molecular similarity search, clinical trial and patent search integrations, and runs on GPU-accelerated infrastructure (e.g., NVIDIA T4) delivered as a SaaS subscription. Typical customers are biopharma and biotech teams collaborating with Optic to scale preclinical pipelines and business due diligence. Optic aims to create a closed-loop, intelligent drug development engine that integrates scientific and business AI.
TL;DR
What they do: AI-native platform (branded BIOPTIC) that applies generative models, ligand-/structure-based modeling and LLM-based agents to accelerate drug discovery and biopharma R&D.
Founders: Andrey Doronichev; Roman Doronin; Vlad Vinogradov
Funding (notable): Seed: $11.0M (Jul 2022) led by Kleiner Perkins and Pantera Capital
Headquarters: San Francisco, United States
Industry: Biotechnology / Pharma AI
Company Overview
Problem Domain
Drug discovery and biopharma R&D (target identification through preclinical validation; research scouting, due diligence, in‑licensing and commercialization support).
Industry
Biotechnology
Tech Stack
Funding Track Record
$11,000,000
Dealroom lists seed amount $11.0M; Crunchbase shows a Seed round dated Jul 20, 2022.
Pre-Seed round dated Mar 1, 2022 is listed in Crunchbase (amount obfuscated in captured view).
Investor Signal
“Seed led by Kleiner Perkins and Pantera Capital; additional investors reported include Greylock Partners, Circle, Pantera Capital, OpenSea, CoinDCX, Polygon, FlamingoDAO, Lattice Capital, Neon DAO and BBQ Capital.”